drugset / Trial / NCT05043194

Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis

NCT05043194

Unknown 80 enrolled Wei Liu
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day after birth in preterm infants who started parenteral nutrition therapy can reduce the occurrence of enteral nutrition-related cholestasis in preterm infants. This study examined the safety and efficacy of ursodeoxycholic acid (UDCA) in preventing Cholestasis Associated with Total Parenteral Nutrition in preterm infants.

Timeline

Start
2021-01-01
Primary completion
2021-09-30
Completion
2022-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 20 mg/kg Oral
Subject Ursodeoxycholic Acid Small molecule 25 mg/kg Oral